Celea Therapeutics
3 known investors
Celea is a biopharmaceutical company developing next-generation therapies for serious respiratory diseases, with a lead antifibrotic drug candidate, deupirfenidone, in Phase 3 development for idiopathic pulmonary fibrosis (IPF). The oral therapy is a modified version of FDA-approved pirfenidone and is being tested in a head-to-head superiority trial against an existing antifibrotic treatment.
BiotechMedical Devices
Investors · 3
Funding
SEC filings, press & company announcements$180M disclosed across 1 of 2 rounds · 2026
- $180MraisedJul 2026 · 3 sources
Leaps by Bayer, PureTech Health, RA Capital Management
Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
In the news
Frequently asked questions
- What does Celea Therapeutics do?
- Celea is a biopharmaceutical company developing next-generation therapies for serious respiratory diseases, with a lead antifibrotic drug candidate, deupirfenidone, in Phase 3 development for idiopathic pulmonary fibrosis (IPF). The oral therapy is a modified version of FDA-approved pirfenidone and is being tested in a head-to-head superiority trial against an existing antifibrotic treatment.
- Who are Celea Therapeutics's investors?
- Celea Therapeutics's investors include RA Capital, Leaps by Bayer, PureTech Health.
- How much funding has Celea Therapeutics raised?
- Celea Therapeutics has disclosed $180M raised across 1 of its 2 known rounds.